YEZTUGO
Jun 30, 2025
Gilead YEZTUGO Makes History with First Twice-Yearly HIV Prevention Drug
Gilead Sciences has received a highly anticipated approval from the FDA for its long-acting HIV prevention injection, YEZTUGO (lenacapavir), marking a significant advancement in HIV prevention. On June 18, 2025, the FDA approved YEZTUGO, an injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrE...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
